ym 529 has been researched along with Osteolysis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goto, H; Kanematsu, T; Miki, T; Muguruma, H; Sone, S; Uehara, H; Yano, S; Zhang, H | 1 |
| Alcalde, RE; Etoh, Y; Kitamura, K; Matsumura, T; Sasaki, A; Suzuki, A; Tanaka, T | 1 |
2 other study(ies) available for ym 529 and Osteolysis
| Article | Year |
|---|---|
A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Carcinoma, Small Cell; Cell Division; Cytokines; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Humans; Imidazoles; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocyte Depletion; Lymphokines; Male; Mice; Mice, SCID; Osteolysis; Parathyroid Hormone-Related Protein; Peptide Hormones; Severe Combined Immunodeficiency; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Imidazoles; Mice; Mice, Nude; Neoplasm Transplantation; Osteolysis | 1998 |